Document:

Exhibit 4.1

Form of Common Stock Certificate

                       Incorporated under the Laws of the
                                 State of Nevada

Number                                                                    Shares

                        The Entertainment Internet, Inc.
                       50,000,000 Shares, $.001 Par Value
                                  Common Stock

     This is to certify that _____________ is the owner of ____________ fully
paid and non-assessable shares of the above Corporation, transferable only on
the books of the Corporation, by the holder hereof in person or by duly
authorized attorney upon surrender of their certificate properly endorsed.

     Witness, the seal of the corporation and the signatures of its duly
authorized officers.

_____________,Secretary           [SEAL]              _______________, PresidentExhibit 10.11

     THIS THIRD  AMENDMENT TO OPTION  AGREEMENT (the "Third  Amendment") is made
and entered into effective December 20, 2002, by and among Atlas Precious Metals
Inc.,  a Nevada  corporation  ("APMI")  and  Atlas  Minerals  Inc.,  a  Colorado
corporation ("AMI"; AMI and APMI will be collectively referred to hereinafter as
"Atlas"),  and Seabridge Gold Inc. (formally known as Seabridge Resources Inc.),
a company  incorporated  under the laws of Canada  ("SGI")  and  Seabridge  Gold
Corporation,  a Nevada  corporation 100% and wholly-owned by SGI ("SGI"; SGI and
SGC will be collectively referred to hereinafter as "Seabridge").

RECITALS

     A. Atlas and Seabridge  entered into an Option Agreement dated effective as
of February  14,  2000 (the  "Agreement"),  pursuant  to which Atlas  granted to
Seabridge an exclusive  option (the  "Option") to purchase the interests held by
Atlas in certain  unpatented mining claims, fee lands and related assets located
in Malheur County, Oregon (collectively, the "Property").

     B. Pursuant to the Agreement (as modified by the first amendment, effective
December 31, 2000 and the second amendment, effective July 31, 2001, in order to
keep the Option in effect, Seabridge is required to timely make certain periodic
payments (the "Option Payments") to Atlas.

     C. The parties now desire to modify the Agreement to extend the term of the
Option and provide for an additional Option Payment to be made.

     NOW,  THEREFORE,  in  consideration  of the  premises  and  of  the  mutual
covenants,  conditions and obligations contained in this Amendment,  the receipt
and  sufficiency  of which the parties  hereby  acknowledge,  the parties hereto
agree to amend the Agreement as follows:

     1. Section 1.3 of the Agreement is hereby revised to read as follows:

     The term of the  Option  (the  "Option  Period")  shall  commence  upon the
Effective Date, and shall continue  through and including the earlier of (a) the
date the Option is exercised, (b) the date this Agreement is terminated pursuant
to Sections 7.1 or 7.2, or (c) March 31, 2003

     2. Section 1.4 of the Agreement is hereby revised to read as follows:

     SGI agrees to timely make the following payments to Atlas during the Option
Period:

         On or Before                     Amount of Payment
         December 31, 2002                U.S.$300,000

<PAGE>

     The  above-referenced  payment (the "Option Payment") shall not be credited
against  the  Purchase  Price.  In  addition,  the Option  Payment  shall not be
refundable  to SGI,  whether or not it  exercises  the Option.  In the event SGI
fails to timely  make the  Option  Payment,  Atlas may elect to  terminate  this
Agreement pursuant to the provisions of Section 7.2 hereof.

     3. Section 1.2 of the Agreement is replaced in its entirety as follows:

     The purchase price (the "purchase  Price") for the purchase of the Property
to be acquired by  Seabridge  if it  exercises  the Option  shall be  US$600,000
payable by delivery to Atlas at the Closing.

     4. Section 1.7(b) of the Agreement is replaced in its entirety as follows:

     Six Hundred Thousand Dollars  (U.S.$600,000)  by wire transfer in immediate
available funds.

     5. Section 2.1(d) of the Agreement is hereby revised to read as follows:

     To the extent the  Agreement  remains in effect  during any  portion of the
month  of  February  of  any  calendar  year,  Seabridge  shall  be  financially
responsible  for the annual  payments  to the Oregon  Department  of Geology and
Mineral  Industries due on or before February 28th of each such year in order to
maintain  the  exploration   permits  listed  on  Exhibit  C  (the  "Exploration
Permits").  Not later  than  February  10th of each such year,  Seabridge  shall
forward to Atlas a wire transfer (in accordance with written  instructions to be
provided  by Atlas) in the  amount  of each of those  payments  (as set forth on
Schedule 2.1 or as provided in written notice from Atlas to  Seabridge).  If the
required amount is timely  forwarded to Atlas,  Atlas shall then be obligated to
timely make the required  payments not later than February  15th, and to provide
evidence of such payments to Seabridge not later than February 20th.

     Except as set forth above, the parties hereby ratify and confirm all of the
terms and conditions of the Agreement (as previously amended).

     IN WITNESS  WHEREOF,  the parties  hereto have caused this  Amendment to be
executed on the date first above written.

                                   ATLAS MINERALS INC.
                                   A Colorado corporation

                                   By: /s/ H.R. Shipes
                                       -------------------------------------
                                       H. Roy Shipes
                                       Chairman and Chief Executive Officer

<PAGE>

                                     ATLAS PRECIOUS METALS INC.
                                     A Nevada corporation

                                     By: /s/ H.R. Shipes
                                         ---------------------------------------
                                         H. Roy Shipes
                                         Chairman and Chief Executive Officer

                                     SEABRIDGE GOLD INC.
                                     A Canada corporation

                                     By: /s/ Rudi P. Fronk
                                         ---------------------------------------
                                         Rudi P. Fronk
                                         Chairman and Chief Executive Officer

                                     SEABRIDGE GOLD CORPORATION

                                     By: /s/ Rudi P. Fronk
                                         ---------------------------------------
                                         Rudi P. Fronk
                                         Chairman and Chief Executive OfficerSUBLICENSE AGREEMENT

         This revised SUBLICENSE AGREEMENT ("Sublicense" or "Agreement") is made
and entered into by BioDelivery  Sciences  International,  Inc. and  BioDelevery
Sciences,  Inc.  (jointly  referred to herein as "BDS") and  RetinaPharma,  Inc.
f/k/a Warex Inc. ("RetinaPharma"),  a Nevada corporation, as of this 10th day of
August, 2001.

                              W I T N E S S E T H:

         WHEREAS,  BDS is developing and  commercializing  a cochleate  delivery
system  pursuant to patents,  pending patent  applications  and  proprietary and
trade secret information (herein the "BDS Technology"); and

         WHEREAS,  RetinaPharma  is developing  and  commercializing  technology
pursuant  to  a  Sublicense   Agreement   dated  January  4,  2001  with  Tatton
Technologies,  LLC ("Tatton") for the treatment of retinal  disease and glaucoma
(the "Tatton Technology"); and

         WHEREAS,  BDS wishes to grant to  RetinaPharma  a Sublicense to the BDS
Technology for the delivery of antiapoptotic  pharmaceutical  and  antiapoptotic
nutriceutical treatment for retinal disease and glaucoma.

         NOW THEREFORE,  for good and valuable consideration,  in hand received,
including the mutual  covenants and promises of the parties as set forth in this
Agreement, the parties mutually agree as follows:

         1.  SUBLICENSE.  During the term of this  Agreement,  BDS hereby grants
RetinaPharma the exclusive worldwide right to commercialize,  manufacture, sell,
market, apply, and utilize the BDS Technology for, but only for, the purposes of
delivery  of   antiapoptotic   pharmaceutical   and   nutriceutical   treatments
specifically  utilizing  the Tatton  Technology  under that  certain  Sublicense
between Tatton  Technologies LLC and RetinaPharma dated January 4, 2001, as same
may be amended  from time to time,  for,  and only for the  purpose of  treating
antiapoptotic  pharmaceutical and nutriceutical treatment of retinal disease and
glaucoma in  conjunction  with the Tatton  Technology  (the  "Designated  Use").
During  the  term of this  Agreement  and  for so long as  RetinaPharma  has not
violated  the terms  hereof,  BDS shall not permit any other person or entity to
use or apply the BDS Technology, or any part thereof, for the Designated Use, as
defined herein,without the prior written permission of RetinaPharma which may be
withheld  in the sole  discretion  of  RetinaPharma.  Other  than  the  specific
restriction  set  forth in the  preceding  sentence,  which  is,  by its  terms,
specifically  limited  to the  Designated  Use as defined  herein,  BDS shall be
unrestricted in all uses and applications of its technology during and following
the term hereof.  Further,  BDS agrees to immediately notify RetinaPharma of any
use, infringement or claim threatened or asserted by any third party relating to
the BDS  Technology  used for the  Designated  Purpose and will  cooperate  with
RetinaPharma  in the defense of such use,  infringement or claim as same relates
to the Designated Use.

<PAGE>

         2.  COMMERCIALIZATION.  RetinaPharma  agrees to exercise its reasonable
efforts to  commercialize  the BDS  Technology  for the  Designated  Use through
commercial  sales,   sublicenses,   joint  development  agreements,   and  other
commercialization  efforts as determined  appropriate in the sole discretion and
judgment of RetinaPharma.

         3.  ROYALTY.  RetinaPharma  agrees  to pay BDS a  royalty  equal to the
greater of the Base Royalty,  as hereinafter  defined or thirty percent (30%) of
all net pretax  profits  (the  "Profits"  as  hereinafter  defined)  plus thirty
percent  (30%)  of all net  proceeds,  if any,  from  the  sale,  assignment  or
sublicense of the BDS  Technology  for the  Designated  Use as permitted  herein
earned  by  RetinaPharma  from  the  sale  of  products  incorporating  the  BDS
Technology.  For purposes  hereof,  Profits,  whether from the sale of products,
sublicenses,  assignments  or other  disposition,  shall be: (i)  computed  in a
consistent manner, in accordance with generally accepted accounting  principles;
and (ii) make reasonable allocation of all costs and expenses including, but not
limited to development  costs and overhead costs,  among its various  activities
(including  those related to the BDS Technology and those which do not relate to
the  BDS  Technology  but  which  relate  to  or  support  the   development  or
commercialization of RetinaPharma  products which are reasonable  anticipated to
utilize  the BDS  Technology)  so that  the  allocation  of  such  expenses  and
royalties  to  the  sale  of  products  incorporating  the  BDS  Technology  are
reasonable  in  relationship  to  the  overall  business  and  activities  being
conducted by  RetinaPharma.  Notwithstanding  the  foregoing,  royalties due BDS
shall not be less than five  percent  (5%) of the  gross  proceeds  realized  by
RetinaPharma in connection with the marketing, sale, assignment or sublicense of
the BDS Technology (the "Gross Proceeds").  RetinaPharma shall pay all royalties
due  hereunder,  on or before the 10th day of each month.  All royalty  payments
shall be accompanied by a written report specifying  Profits and Gross Proceeds.
BDS shall have the right to inspect the books and records of RetinaPharma at any
reasonable time during normal business hours.

         4. SUBLICENSE AND ASSIGNMENT. RetinaPharma may sublicense or assign the
BDS Technology, or any part thereof, for the Designated Uses, in the exercise of
its discretion  provided that the assignee or sub licensee is bound by the terms
of this Agreement which are applicable thereto and that the appropriate royalty,
as provided in Paragraph 3 above,  is paid to BDS. Any  sublicense or assignment
shall require the prior written approval of BDS, which shall not be unreasonably
withheld and which may provide reasonable  protection that any Royalties due BDS
will be timely paid and imposing  termination  provisions  in the  Sublicense or
Assignment  in the event of failure to timely pay  Royalties.  In the event of a
subsequent merger of any of the parties hereto, this Agreement shall continue to
be binding on and  enforceable  against the  successor  to such party and to the
other parties to this Agreement.

<PAGE>

         5.  REPRESENTATIONS  AND  WARRANTIES  OF BDS.  BDS makes the  following
representations and warranties to RetinaPharma,  each of which shall survive the
closing of this Agreement:

         a) BDS is the  licensee  of the BDS  Technology,  subject to no claims,
interests,  or rights of any third party,  which are inconsistent  with or which
will be breached by virtue of this Agreement.

         b) BDS has full right and authority to enter into this Agreement and to
perform its obligations hereunder.

         c) BDS  agrees  to  cooperate  with  RetinaPharma  to  defend  the  BDS
Technology for the Designated Uses from  infringement upon the rights thereof by
any third party.

         d) The grant of this  Sublicense does not require the prior approval of
any third party which has not been  obtained  and does not violate or breach any
agreement, license, or other obligations to which BDS is a party or to which the
BDS Technology is subject.

         6.  REPRESENTATIONS AND WARRANTIES OF RETINAPHARMA.  RetinaPharma makes
the following representations and warranties to BDS, each of which shall survive
the closing:

         a)  RetinaPharma  has full  right  and  authority  to enter  into  this
Agreement and to perform its obligations hereunder.

         b) The execution of this Agreement by RetinaPharma  will not breach any
agreement to which RetinaPharma is a party.

         c) Entering  into and  carrying out of this  Agreement by  RetinaPharma
does not require the consent or approval of any party,  which has not given such
consent or approval.

         d)  RetinaPharma  will  exercise  reasonable  efforts and good faith to
commercialize the BDS Technology for Designated Uses.

         7.  NON-FRUSTRATION.  Neither party to this Agreement  shall commit any
act or take any action  that would  frustrate  or hamper the rights of the other
party  under this  Agreement.  Each party  shall act in good faith and engage in
fair dealing when taking any action under or related to this Agreement.

         8.  TERM.  This  Agreement  shall  continue  in  effect  for so long as
RetinaPharma  is using the BDS Technology for the Designated  Uses. In the event
of a material breach of this Agreement,  the  non-breaching  party may terminate
this  Agreement  providing  the material  default is not cured by the  breaching
party  within 30 days  written  notice  specifying  the event of default and the
intention to terminate.  RetinaPharma  may terminate this Agreement upon 30 days
written notice provided that it is current in the payment of all Royalties.

<PAGE>

         9.  ARBITRATION.  Any dispute  arising  under this  Agreement  shall be
resolved  solely  by  binding   arbitration  before  the  American   Arbitration
Association located in St. Louis, Missouri. The finding of the arbitrators shall
be final and  binding  and shall  constitute  the sole and  exclusive  means for
resolving  any  dispute  under  this  Agreement.   The  rules  of  the  American
Arbitration   Association   shall  be  binding   upon  said   arbitration.   The
determination  of arbitrators may be reduced to a final judgment in any court of
competent jurisdiction.

         10. MISCELLANEOUS.

                  (i) This Agreement constitutes the entire understanding of the
parties and shall not be amended or otherwise  altered,  except in writing,  and
executed by the parties hereto.  This Agreement  supersedes and replaces any and
all prior oral and written agreements regarding the subject matter hereof.

                  (ii)  RetinaPharma and BDS each  acknowledges  that certain of
their shareholders  including,  but not limited to the Hopkins Capital Group and
its  affiliates,  are  stockholders  and/or  members  of  management  of BDS and
RetinaPharma (the "Overlapping and Conflicted  Interest").  Such Overlapping and
Conflicted  Interest  has  been  the  subject  of  full  disclosure  and BDS and
RetinaPharma  have each had the  opportunity to ask questions and obtain further
information regarding the Overlapping and Conflicted Interest.  RetinaPharma and
BDS,  by  virtue  of the  execution  of this  Agreement,  expressly  waived  the
Overlapping  and  Conflicted  Interest and any conflicts of interest,  which may
result  therefrom.  By execution of this Agreement,  BDS and  RetinaPharma  each
waive said  Overlapping and Conflicted  Interest and the resulting  conflicts of
interest  as a defect or defense  with regard to this  Agreement  or the subject
matter hereof

                  (iii) This Agreement  shall not be construed more  stringently
against  either  party,  regardless  of  which  party  may  have  served  as the
draftsman.

                  (iv)    This Agreement and the resolution of any dispute shall
                          be governed by the laws of the State of Missouri.

                  (v)     This  Agreement has been prepared by Samuel S. Duffey,
                          Duffey & Dolan,  PA, which has, in the past,  and may,
                          in the future,  provide advice or consultation to BDS,
                          RetinaPharma  and  Hopkins  Capital  Group  and  their
                          affiliates ("Disclosed  Relationships").  Further, Mr.
                          Duffey  has   disclosed   that   entities   or  Trusts
                          affiliated with members of his family are stockholders
                          of BDS and RetinaPharma.

<PAGE>

                          Mr. Duffey has advised BDS and RetinaPharma and Tatton
                          that he  represented  and gave  advise  to no party to
                          this  Agreement,  including  but not  limited to, BDS,
                          RetinaPharma,  Tatton nor Hopkins Capital Group in the
                          preparation  of this Agreement and that each party was
                          advised  of their  right to consult  with  independent
                          legal counsel.  BDS and RetinaPharma,  by execution of
                          this  Agreement,  each expressly waive and release Mr.
                          Duffey  and  Duffey  &  Dolan,  PA  from  any  and all
                          conflicts of interest related to or resulting from the
                          Disclosed  Relationships or otherwise  related to this
                          Agreement or the subject matter hereof.

         IN WITNESS WHEREOF, the parties have set their hand and seal on the day
and year first above written.

                          BioDelivery Sciences International, Inc.

                          By: /s/ Raphael Mannino
                              ----------------------------------------------
                              Raphael Mannino
                              President

                          BioDelevery Sciences International, Inc.

                          By: /s/ Donald C. Ferguson
                              ----------------------------------------------
                              Donald C. Ferguson, Senior Executive President

                          RetinaPharma, Inc.

                          By:/s/ Frank E. O'Donnell, Jr.
                             ----------------------------------------------
                             Frank E. O'Donnell, Jr., MD
                             Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]